Skip to content
Screener

CRISPR Therapeutics CRSP Prepaid & Other Current

Prepaid & Other Current at other companies

Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$82.75M+232%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$6.41M-44.4%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$55.3M+99.9%
Sana Biotechnology logo
Sana BiotechnologySANA
$6.36M+65.8%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$4.23M+6.4%
Prime Medicine logo
Prime MedicinePRME
$1.36M-55.2%

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$5.17B+2.7%
Enterprise value$5.54B+9.4%
P/S1,261.3×+1,129×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:48 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204188
Line itemAs of / March 31, 2026As of / December 31, 2025
Current assets:
Cash and cash equivalents$423,308$347,559
Marketable securities2,018,4771,628,269
Prepaid expenses and other current assets6,5779,843
Total current assets2,448,3621,985,671
Property and equipment, net112,175115,851
Restricted cash7,6297,629
Operating lease assets128,671131,724

Item 1. Financial Statements

FAQ

What is CRISPR Therapeutics's prepaid & other current?
CRISPR Therapeutics (CRSP) reported prepaid & other current of $6.58M in Q1 2026.
How has CRISPR Therapeutics's prepaid & other current changed year-over-year?
CRISPR Therapeutics's prepaid & other current decreased by 46.6% year-over-year, from $12.33M to $6.58M.
What is the long-term trend for CRISPR Therapeutics's prepaid & other current?
Over 5 years (2020 to 2025), CRISPR Therapeutics's prepaid & other current has grown at a -17.7% compound annual growth rate (CAGR), from $26.14M to $9.84M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.

Ask your AI about CRISPR Therapeutics's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude